HC Wainwright & Co. Maintains Buy on Maze Therapeutics, Raises Price Target to $110

HC Wainwright & Co. analyst Ananda Ghosh has maintained a Buy rating on Maze Therapeutics (NASDAQ: MAZE) and raised the price target from $60 to $110. This adjustment reflects a positive outlook for the company's performance.